An experimental cancer vaccine developed at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy has shown early promise in a Phase I clinical trial for a rare form of liver cancer that primarily affects children and young adults.
Experimental liver cancer vaccine shows promise for young patients in early trial
